# Generate Biomedicines, Inc.: overview GENB · Nasdaq · CIK 2100782 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/genb.md) · [Financials](/companies/genb/financials.md) · [Filings](/companies/genb/filings.md) · [Insiders](/companies/genb/insiders.md) Latest reported revenue: [$6.3m](/filings/0001193125-26-336437.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-336437). ## Last eight quarters | Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | [8.8](/filings/0001193125-26-210059.md) | [10.1](/filings/0001193125-26-336437.md) | [7.2](/filings/0001193125-26-210059.md) | [6.3](/filings/0001193125-26-336437.md) | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | [(546.1%)](/filings/0001193125-26-210059.md) | [(593.8%)](/filings/0001193125-26-336437.md) | [(887.5%)](/filings/0001193125-26-210059.md) | [(1134.2%)](/filings/0001193125-26-336437.md) | | Net margin | % | [(472.7%)](/filings/0001193125-26-336437.md) | [(517.6%)](/filings/0001193125-26-336437.md) | [(850.6%)](/filings/0001193125-26-336437.md) | [(1065.2%)](/filings/0001193125-26-336437.md) | | Diluted EPS | $ per share | [(1.62)](/filings/0001193125-26-210059.md) | [(1.94)](/filings/0001193125-26-336437.md) | [(1.07)](/filings/0001193125-26-210059.md) | [(0.52)](/filings/0001193125-26-336437.md) | | Free cash flow | $m | [(53.9)](/filings/0001193125-26-210059.md) | [(48.9) d](/filings/0001193125-26-336437.md) | [(84.2)](/filings/0001193125-26-210059.md) | [(58.9) d](/filings/0001193125-26-336437.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure. ## Last five fiscal years Not reported. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/genb/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Flagship Pioneering, LLC](/funds/1400240.md) | 2026-06-30 | $1.06bn | 62,673,117 | | Unchanged | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $88.1m | 5,221,599 | | Added +1,004,075 | | [Capital World Investors](/funds/1422849.md) | 2026-06-30 | $71.1m | 4,215,632 | | Added +211,483 | | [BRAIDWELL LP](/funds/1920938.md) | 2026-06-30 | $55.4m | 3,283,844 | | Reduced −309,155 | | [NORGES BANK](/funds/1374170.md) | 2026-06-30 | $35.3m | 2,094,616 | | New +2,094,616 | | [ARCH Venture Management, LLC](/funds/1274403.md) | 2026-06-30 | $32.8m | 1,944,426 | | Unchanged | | [HarbourVest Partners LLC](/funds/1201001.md) | 2026-06-30 | $29.1m | 1,722,210 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $28.0m | 1,659,966 | | New +1,659,966 | | [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $24.0m | 1,423,602 | | Unchanged | | [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $23.8m | 1,409,649 | | Reduced −1,537,610 | ## Recent filings [All 53 filings](/companies/genb/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-26 | 19:28 ET | [8-K](/filings/0001193125-26-365556.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-365556 | | 2026-08-06 | 06:01 ET | [10-Q](/filings/0001193125-26-336437.md) | Quarterly report, period 2026-06-30 | 0001193125-26-336437 | | 2026-08-06 | 06:00 ET | [8-K](/filings/0001193125-26-336462.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-336462 | | 2026-05-07 | 06:01 ET | [10-Q](/filings/0001193125-26-210059.md) | Quarterly report, period 2026-03-31 | 0001193125-26-210059 | | 2026-05-07 | 06:00 ET | [8-K](/filings/0001193125-26-209899.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-209899 | | 2026-03-02 | 17:22 ET | [8-K](/filings/0001193125-26-085780.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-085780 | | 2026-02-23 | 06:37 ET | [S-1/A](/filings/0001193125-26-062362.md) | Registration statement, amended | 0001193125-26-062362 | | 2026-02-13 | 17:15 ET | [S-1/A](/filings/0001193125-26-051761.md) | Registration statement, amended | 0001193125-26-051761 | | 2026-02-04 | 17:02 ET | [S-1](/filings/0001193125-26-037799.md) | Registration statement | 0001193125-26-037799 | ## Latest annual report No annual report is in coverage. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/21079957-bdb9-48c7-8fe5-d25a61bf9c02) ## About the filer - CIK: 2100782 - Tickers: GENB - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:13 ET. No prices; not investment advice.